May 12, 2021

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE 1st Section)
Contact person: Kenji Yamada, Senior Vice President,
Corporate Administration Headquarters
(TEL. +81-3-6711-5200)

Japan Lifeline Finalizes Supply Agreement for Pulsed Electric Field Ablation Catheter for U.S. Market

Japan Lifeline Co., Ltd. is pleased to announce that it has entered into a development and supply agreement with Galaxy Medical, Inc. (U.S.) for a pulsed electric field (PEF) ablation catheter for the U.S. market.

Pulsed electric fields are the electric fields generated when high-voltage is applied for a short period of time. PEF has been investigated and applied as a treatment method for cardiac arrythmias through electroporation, which induces cellular apoptosis (cell death) and ultimately blocking conduction of irregular heart signals. Because of being a non-thermal energy in nature, and thus maintaining the integrity of nerves and vessels within close proximity to the target tissue, the risk of damage to the esophagus, phrenic nerve or other surrounding structures is anticipated to be reduced.

Galaxy Medical was founded in 2020 as a developer of PEF technology. With its aim to apply its proprietary technology to the treatment of cardiac arrhythmias, it has developed the Centauri PEF System, a generator system for PEF treatment of cardiac arrythmias. In this agreement, Japan Lifeline supplies Galaxy Medical with the Alpha1, which is an ablation catheter developed by the company, and Galaxy Medical will sell the product in combination with the generator system in the U.S. market.

Alpha1 is a dedicated catheter for the Centauri PEF System. It is used to perform point-by-point ablation with its catheter-tip electrodes, and it is capable for use in a wide range of cases. In addition, physicians will have access to the Centauri Connect Box so that they can use the latest PEF technology with conventional mapping systems without any significant changes in the current ablation procedures. The Centauri Systems proprietary WAVE1 technology is optimized to eliminate the incidence of microbubbles that can cause cerebral infarction and other complications.

Galaxy Medical will undertake the IDE[*1] clinical trial for the Alpha1 and Centauri System in the U.S. this year.

Japan Lifeline is thrilled to work with Galaxy Medical with its wealth of knowledge and unique PEF ablation technology. Japan Lifeline is eager to help establish the PEF treatment for cardiac arrhythmias in the U.S., and

also to bring the latest treatment to Japan.

About Galaxy Medical

Galaxy Medical (www.galaxymed.com) is a privately held medical device company based in San Carlos, CA, that is dedicated to developing therapies to treat patients with cardiac arrhythmias. Formed by ATP, a leader in life sciences venture capital, Galaxy is building a portfolio of technologies to address the needs of cardiac electrophysiologists.

Note[*1] IDE: Investigational Device Exemption